1Newman-Tancredi A, Heusler P, Martel J C, et al. Agonist and antagonist properties of antipsychotics at human dopamine D4. 4 receptors: G-protein activation and K channel modulation in transfected cells [ J ]. Int J Neuropsychopharmacol,2007,26( 1 ) :1-15.
2Tadori Y, Kitagawa H, Forbes R A, et al. Differences in agonist/antagonist properties at human dopamine D (2) receptors between aripiprazole, bifeprunox and SDZ 208-912 [ J ]. Eur J Pharmacol,2007,28 ( 3 ) : 103-121.
3Bruins Slot L A, Palmier C, Tardif S, et al. Action of novel antipsychotics at human dopamine D3 receptors coupled to G protein and ERK1/2 activation [ J ]. Neuropharmacology, 2007,53 ( 1 ) :232-241.
4Novi F,Millan M J,Corsini G U,et al. Partial agonist actions of aripiprazole and the candidate antipsychotics $33592, bifeprunox, N-desmethylclozapine and preclamol at dopamine D(2L) receptors are modified by co-transfection of D (3) receptors: potential role of heterodimer formation[ J]. J Neurochem. 2007.102 ( 4 ) : 1410- 1424.
5Millan M J, Iob L, Peglion J L, et al. Discriminative stimulus properties of $32504,a novel D3/D2 receptor agonist and antiparkinson agent,in rats: attenuation by the antipsychotics, aripiprazole, blfeprunox, N-desmethylclozapine, and by selective antagonists at dopamine D2 but not D3 receptors [ J ]. Psychopharmacology (Berl) ,2007,191 ( 3 ) :767-782.
6Assie M B, Dominguez H, Consul-Denjean N, et al. In vivo occupancy of dopamine D2 receptors by antipsychotic drugs and novel compounds in the mouse striatum and olfactory tubercles[ J ]. Naunyn Schmiedebergs Arch Pharmacol, 2006, 373(6) :441-450.
7Cosi C, Carilla Durand E, Assie M B, et al. Partial agonist properties of the antipsychotics SSRI 81507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release [ J ]. Eur J Pharmacol, 2006,535 ( 1- 3) :135-144.
8Rauly-Lestienne I, Boutet-Robinet E, Ailhaud M C,et al. Differential profile of typical, atypical and third generation anti-psychotics at human 5-HT(7a) receptors coupled to adenylyl cyclase:detection of agonist and inverse agonist properties [ J ]. Naunyn Schmiedebergs Arch Pharmacol, 2007,9 (5) :66-69.
9Auclair A L, Galinier A, Besnard J, et al. Putative antipsy-chotics with pronounced agonism at serotonin 5-HT1A and partial agonist activity at dopamine D2 receptors disrupt basal PPI of the startle reflex in rats [ J ]. Psychopharmacology (Berl) ,2007,193 ( 1 ) :45-54.
10Kleven M S, Barret Grevoz C, Slot L B, et al. Novel antipsychotic agents with 5-HT ( 1A ) agonist properties : role of 5- HT(1A) receptor activation in attenuation of catalepsy induction in rats [ J ]. Neuropharrnacology, 2005,49 ( 2 ) : 135- 143.
